Isomorphic Labs secures $5 billion for clinical drug development
Isomorphic Labs has raised $5 billion in a Series C funding round to advance its drug candidates toward clinical trials. The company was spun out of Google’s DeepMind in 2021. Greenoaks and Sequoia Capital co-led the round, joined by new investor Andreessen Horowitz and other participants. Existing backers, including GV, Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund, also invested.
The company develops an AI drug-design engine that uses simulation models to examine different areas of chemistry. Its work builds on DeepMind’s AlphaFold system, which predicts the three-dimensional structure of proteins from their genetic sequence. Isomorphic Labs said the program has produced positive preclinical results in oncology and immunology, and it has agreements with Eli Lilly, Novartis, and Johnson & Johnson.
The capital will support further development of the platform and expansion into additional types of medicine. The round follows a $2.1 billion Series B completed in May. Isomorphic Labs did not disclose a valuation. Bloomberg previously reported that the company was seeking a valuation of $50 billion. Founder and CEO Demis Hassabis is focusing on drug discovery and has moved into a chairman role at DeepMind.
Written by Sakhanda Wire AI from reporting by TechCrunch. Facts, quotes and full context are in the original article below.